Immunohistochemical localization of transforming growth factor β-1 and its relationship with collagen expression in advanced liver fibrosis due to biliary atresia

Clinical and Experimental Gastroenterology

Volumn 3, Issue 1, 2010, Pages 185-191

  Farrington, Christian ^a   Novak, Don ^a   Liu, Chen ^a   Haafiz, Allah B ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Biliary atresia; Liver fibrosis; Liver transplantation; Transforming growth factor 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ARTICLE; BILE DUCT ATRESIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROGENESIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER FIBROSIS; LIVER NODULE; LIVER PARENCHYMA; MALE; MYOFIBROBLAST; PARACRINE SIGNALING; PRESCHOOL CHILD; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SCHOOL CHILD; TISSUE DISTRIBUTION;

EID: 78650542557     PISSN: None     EISSN: 11787023     Source Type: Book Series    
DOI: None     Document Type: Article

References (45)

1. Narkewicz MR. Biliary atresia: an update on our understanding of the disorder. Curr Opin Pediatr. 2001;13(5):435-440.
2. Davenport M, Howard ER. Macroscopic appearance at portoenteros-tomy - a prognostic variable in biliary atresia. J Pediatr Surg. 1996; 31(10):1387-1390.
3. Shteyer E, Ramm GA, Xu C, White FV, Shepherd RW. Outcome after portoenterostomy in biliary atresia: pivotal role of degree of liver fbrosis and intensity of stellate cell activation. J Pediatr Gastroenterol Nutr. 2006;42(1):93-99.
4. Weerasooriya VS, White FV, Shepherd RW. Hepatic fbrosis and survival in biliary atresia. J Pediatr. 2004;144(1):123-125.
5. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124(1): 105-117.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348(9):800-807.
7. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61-68.
8. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fbrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303-1313.
9. Adrian JE, Kamps JA, Scherphof GL, et al. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fbrotic livers of bile duct ligated rats. Biochim Biophys Acta. 2007;1768(6):1430-1439.
10. Bolkenius U, Hahn D, Gressner AM, Breitkopf K, Dooley S, Wickert L. Glucocorticoids decrease the bioavailability of TGF-beta which leads to a reduced TGF-beta signaling in hepatic stellate cells. Biochem Biophys Res Commun. 2004;325(4):1264-1270.
11. Caligiuri A, de Franco RM, Romanelli RG, et al. Antifbrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology. 2003;124(2):504-520.
12. Chen A, Beno DW, Davis BH. Suppression of stellate cell type I collagen gene expression involves AP-2 transmodulation of nuclear factor-1-dependent gene transcription. J Biol Chem. 1996;271(42): 25994-25998.
13. Kanzler S, Baumann M, Schirmacher P, et al. Prediction of progressive liver fbrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat. 2001;8(6): 430-437.
14. Nelson DR, Gonzalez-Peralta RP, Qian K, et al. Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepat. 1997;4(1):29-35.
15. Williams EJ, Gaca MD, Brigstock DR, Arthur MJ, Benyon RC. Increased expression of connective tissue growth factor in fbrotic human liver and in activated hepatic stellate cells. J Hepatol. 2000;32(5):754-761.
16. van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem. 1988; 263(16):7741-7746.
17. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofbroblast: one function, multiple origins. Am J Pathol. 2007;170(6):1807-1816.
18. Li Z, Dranoff JA, Chan EP, Uemura M, Sevigny J, Wells RG. Transforming growth factor-beta and substrate stiffness regulate portal fbroblast activation in culture. Hepatology. 2007;46(4):1246-1256.
19. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275(4): 2247-2250.
20. Bataller R, Brenner DA. Liver fbrosis. J Clin Invest. 2005;115(2): 209-218.
21. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofbroblast subpopulations in fbrotic human and rat livers. J Hepatol. 2002;36(2):200-209.
22. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20(1 Pt 1):15-20.
23. Haafz AB. Liver fbrosis in biliary atresia. Expert Rev Gastroenterol Hepatol. 2010;4(3):335-343.
24. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55(3): 403-408.
25. Gomez-Dominguez E, Mendoza J, Garcia-Buey L, et al. Transient elastography to assess hepatic fbrosis in primary biliary cirrhosis. Aliment Pharmacol Ther. 2008;27(5):441-447.
26. Staub F, Tournoux-Facon C, Roumy J, et al. Liver fbrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring. Eur Radiol. 2009;19(8):1991-1997.
27. Grewal D, Jain R, Brar GS, Grewal SP. Pentacam tomograms: a novel method for quantifcation of posterior capsule opacifcation. Invest Ophthalmol Vis Sci. 2008;49(5):2004-2008.
28. Moreira RK. Hepatic stellate cells and liver fbrosis. Arch Pathol Lab Med. 2007;131(11):1728-1734.
29. Gressner OA, Weiskirchen R, Gressner AM. Evolving concepts of liver fbrogenesis provide new diagnostic and therapeutic options. Comp Hepatol. 2007;6:7.
30. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepato-cytes in liver fbrosis via epithelial to mesenchymal transition. J Biol Chem. 2007;282(32):23337-23347.
31. Armstrong MJ, Carey MC. The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res. 1982;23(1):70-80.
32. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses. 1986;19(1):57-69.
33. Greim H, Czygan P, Schaffner F, Popper H. Determination of bile acids in needle biopsies of human liver. Biochem Med. 1973;8(2): 280-286.
34. Jansen PL, Strautnieks SS, Jacquemin E, et al. Hepatocanalicular bile salt export pump defciency in patients with progressive familial intra-hepatic cholestasis. Gastroenterology. 1999;117(6):1370-1379.
35. Pastor A, Collado PS, Almar M, Gonzalez-Gallego J. Antioxidant enzyme status in biliary obstructed rats: effects of N-acetylcysteine. J Hepatol. 1997;27(2):363-370.
36. Jones BA, Rao YP, Stravitz RT, Gores GJ. Bile salt-induced apoptosis of hepatocytes involves activation of protein kinase C. Am J Physiol. 1997;272(5 Pt 1):G1109-G1115.
37. Svegliati-Baroni G, Ridolf F, Hannivoort R, et al. Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology. 2005;128(4):1042-1055.
38. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA. 1995;92(7):2572-2576.
39. Kanzler S, Lohse AW, Keil A, et al. TGF-beta1 in liver fbrosis: an inducible transgenic mouse model to study liver fbrogenesis. Am J Physiol. 1999;276(4 Pt 1):G1059-G1068.
40. Thompson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB, Sporn MB. Expression of transforming growth factor-beta 1 in spe-cifc cells and tissues of adult and neonatal mice. J Cell Biol. 1989; 108(2):661-669.
41. Assoian RK, Fleurdelys BE, Stevenson HC, et al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA. 1987;84(17):6020-6024.
42. Lamireau T, Le Bail B, Boussarie L, et al. Expression of collagens type I and IV, osteonectin and transforming growth factor beta-1 (TGFbeta1) in biliary atresia and paucity of intrahepatic bile ducts during infancy. J Hepatol. 1999;31(2):248-255.
43. Ramm GA, Nair VG, Bridle KR, Shepherd RW, Crawford DH. Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fbrogenesis in biliary atresia. Am J Pathol. 1998;153(2):527-535.
44. Bedossa P, Paradis V. Liver extracellular matrix in health and disease. J Pathol. 2003;200(4):504-515.
45. Urushihara N, Iwagaki H, Yagi T, et al. Elevation of serum interleu-kin-18 levels and activation of Kupffer cells in biliary atresia. J Pediatr Surg. 2000;35(3):446-449.